Tools
Stock profile

AbbVie Inc. (ABBV)

ABBV · Latest close $286.01 as of Nov 18, 2026 · 13F data as of Jun 30, 2026 (2026 Q2)
Latest close
$286.01
As of Nov 18, 2026
Tracked funds holding
15 of 149
2026 Q2 13F filings
Opened / added
1 / 2
vs previous quarter
Trimmed / exited
9
vs previous quarter

AbbVie Inc. (ABBV) is held by 15 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 1 fund opening new positions, 2 funds adding, and 9 funds trimming or exiting versus the previous quarter. Insiders were net sellers over the last 90 days ($0 bought vs $11.9M sold). 0 members of Congress reported 0 purchases vs 2 sales. Latest close $286.01 as of Nov 18, 2026.

Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Nov 9, 2026 · Congress to Nov 16, 2026.

Funds
2026 Q2 13F
Insiders · 90d
net $-11.9M
Congress
0 buys vs 2 sales
Fundamentals
Revenue · FY2025
Red flags
none flagged
Short interest
as of Oct 15, 2026
Holdings · Charts · All institutions · Fundamentals · Short interest · Fails to deliver · Insider trading · 5% holders · Planned sales · Politician trading · Committee jurisdiction · Government relations · Screens & lenses · Signal record · Related stocks · Recent 8-K

Funds holding this

Guinness Asset Management · Saturna Capital · Torray Investment Partners LLC — 15 tracked funds hold ABBV. See all holders.

Insider and Congress activity

Insiders bought on the open market (0 purchases, $0) vs 1 sale ($11.9M). Insider trading 0 members of Congress reported buying (0 purchases vs 2 sales). Politician trading

Often held alongside

ISHARES RUSSELL 1000 ETF (IWB) · AMGEN INC (AMGN) · 3M CO (MMM) · CINTAS CORP (CTAS) · NORTHROP GRUMMAN CORP /DE/ (NOC) — stocks the same funds also hold. See all related stocks.

Super-investor holdings · 2026 Q2

FundPortfolio weightSharesChange vs prev. quarter
Guinness Asset Management4.42%1,042,337TRIMMED (-5.3%) Q3 filed Nov 5
Saturna Capital2.94%958,069ADDED (+22.6%) Q3 filed Nov 16
Torray Investment Partners LLC2.80%82,602TRIMMED (-11.7%) Q3 filed Oct 30
Thornburg Investment Management1.30%541,146ADDED (+7.6%) Q3 filed Nov 13
GQG Partners0.90%1,921,614NEW Q3 filed Nov 13
Matrix Asset Advisors0.80%39,070TRIMMED (-0.3%) Q3 filed Oct 13
Harding Loevner0.66%279,294TRIMMED (-21.9%) Q3 filed Nov 16
Sanders Capital0.12%483,963TRIMMED (-6.3%) Q3 filed Nov 2
Edgewood Management0.12%45,542HELD Q3 filed Nov 12
Mairs & Power Funds0.10%44,702TRIMMED (-1.4%) Q3 filed Nov 16

Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.

Price change since quarter-end: +16.6% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.

Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.

Charts

295.03161.432024-11-192026-11-18

Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.

222016Q3: 17 funds2016Q4: 17 funds2017Q1: 17 funds2017Q2: 18 funds2017Q4: 18 funds2018Q1: 17 funds2020Q1: 16 funds2020Q2: 19 funds2020Q3: 19 funds2020Q4: 22 funds2021Q1: 20 funds2021Q2: 21 funds2021Q3: 19 funds2021Q4: 18 funds2022Q1: 18 funds2022Q2: 17 funds2022Q3: 17 funds2023Q2: 17 funds2023Q3: 19 funds2023Q4: 18 funds2024Q1: 18 funds2016Q32024Q1

Tracked funds holding this stock, by quarter (2016Q3–2024Q1, 21 quarters). Source: quarterly BEST lists from 13F filings — tracked funds only, not all filers. A stock appears here only if it ever made a quarterly BEST list.

All institutions · Form 13F

Institutions holding4,226 of 8,857 filers
Long-only filers among them4,211
Change vs 2026 Q1+178 net · 2,157 entered · 1,979 exited
Shares reported, all filers1,321,536,466
Reported value, all filers$326.8B

Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).

Company fundamentals

ExchangeNYSE
IndustryPharmaceutical Preparations (SIC 2834)
Revenue · FY2025$61.2B
Net income · FY2025$4.2B
Total assets · FY2025$134.0B
Shares outstanding1,767,117,285
Market cap (at latest close)$505.4B

Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Jul 27, 2026.

Short interest

Shares short · Oct 15, 202615,582,821
Share of shares outstanding0.88%
Days to cover2.72

Shares short at recent settlements — Jul 31, 2026: 22.5M · Aug 14, 2026: 18.3M · Aug 31, 2026: 19.5M · Sep 15, 2026: 19.5M · Sep 30, 2026: 16.3M · Oct 15, 2026: 15.6M.

Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Jul 27, 2026.

Fails to deliver

Shares failed to deliver · Oct 14, 20260
Share of shares outstanding0.00%
Fails as a share of short interest · Oct 15, 20260.0%

Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 0 · Aug 31, 2026: 0 · Sep 15, 2026: 0 · Sep 30, 2026: 0 · Oct 14, 2026: 0.

Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Jul 27, 2026.

Insider trading · Form 4

0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 1 sale by 1 insider ($11.9M).

Source: SEC Form 4 filings. Open-market transactions only.

Recent open-market trades

DateInsiderRoleBuy / SellSharesPriceValueSource
Nov 9, 2026Stewart Jeffrey RyanEVP, CHIEF COMMERCIAL OFFICERSell40,619$293.60$11.9MSEC filing

Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.

Planned sales · Form 144

FiledSellerRoleShares to sellMarket valueApprox. sale dateSource
Aug 14, 2026NICHOLAS DONOGHOEOfficer32,710$8.2MAug 14, 2026SEC filing
May 26, 2026ROBERT J ALPERNDirector13,000$2.8MMay 26, 2026SEC filing
Mar 6, 2026David R. PurdueOfficer5,230$1.2MMar 4, 2026SEC filing
Mar 2, 2026PERRY C SIATISOfficer18,668$4.4MMar 2, 2026SEC filing
Feb 25, 2026PERRY C SIATISOfficer22,381$5.1MFeb 25, 2026SEC filing
Aug 22, 2025Richard A. GonzalezFormer Director62,755$13.2MAug 22, 2025SEC filing
Aug 21, 2025Richard A. GonzalezFormer Director90,000$19.0MAug 21, 2025SEC filing
Aug 12, 2025AZITA SALEKI-GERHARDTOfficer42,370$8.4MAug 12, 2025SEC filing
Aug 8, 2025Richard A. GonzalezFormer Director61,500$12.0MAug 1, 2025SEC filing
Aug 5, 2025NICHOLAS DONOGHOEOfficer13,299$2.6MAug 5, 2025SEC filing

A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.

5% holders · Schedule 13D/G

FiledFilerFormShares% ownedEvent dateSource
Apr 29, 2026Vanguard Capital ManagementSC 13G132,924,0587.5%Mar 31, 2026SEC filing
Mar 26, 2026The Vanguard GroupSC 13G/A00.0%Mar 13, 2026SEC filing
Jul 7, 2025The Vanguard GroupSC 13G/A177,266,70310.0%Jun 30, 2025SEC filing

One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.

Politician trading · U.S. Congress

0 members of Congress reported buying (0 purchases vs 2 sales).

Source: U.S. House Clerk and U.S. Senate eFD STOCK Act periodic transaction reports, as of Nov 16, 2026. Reported amounts are ranges, and reports can arrive up to 45 days after the trade.

Recent activity by member

MemberChamberPartyBuysSellsLatestAmount range
Sessions, PeteHouseR01Sep 14, 2026$15,001 - $50,000
Gottheimer, JoshHouseD01May 5, 2026$1,001 - $15,000

Member-level activity in the current window, most recent first (House data to Nov 16, 2026, Senate to Oct 1, 2026). House reports arrive as PDFs without transaction-level rows in the current corpus, so this table shows per-member totals, not individual trades; the member page lists the underlying filings. Senate rows link the same way — the member page carries the eFD filing links.

Committee jurisdiction

Industry: Pharmaceutical Preparations (SIC 2834). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.

None of the members who traded this stock in the current window sit on these committees.

Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.

Government relations

Lobbying: 481 Lobbying Disclosure Act filings named this company as client, 2013–2026; most common issues: Health Issues (392), Medicare/Medicaid (245), Taxation/Internal Revenue Code (228).

Federal contracts: no obligated amounts found for this ticker (USASpending, fiscal years 2021–2026).

Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.

Screens & lenses

Financial Screens

· Buffett — Companies with high ROE sustained for more than a decade

· Dividend Growth — Dividends raised for more than 10 years

· Earnings Quality (Cash Conversion) — Profits that actually come back as cash

· Earnings Stability — Small earnings swings and almost no loss years

Chart Signals

· Monthly Uptrend — Price above its 12-month moving average

· Top Relative Strength — Top 20% of the universe by 6-month return

Key figures

· Buffett — Latest ROE: 128.7% · Years ROE ≥15% (of 10): 10 · 10-yr avg ROE: 91.1% · Latest net income: $4.3B

· Dividend Growth — Dividend per share: 6.65 · Dividend yield: 2.3% · Straight dividend years: 13 · 10-yr dividend growth: 183.0%

· Earnings Quality (Cash Conversion) — Cash conversion (3-yr avg): 4.53 · Operating cash flow: $19.0B · Net income: $4.2B

· Earnings Stability — Earnings variation (CV): 0.41 · Loss years (of 10): 0 · Latest net income: $4.2B

Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.

Signal record

· Super-investor 13F BEST — appeared in 21 of the last 40 quarterly lists; latest 2024 Q1, ranked #46 of 50.

· Politician BEST — appeared in 11 of the last 20 quarterly lists; latest 2025 Q3, ranked #28 of 50.

13F signal (2021 Q3 – 2026 Q1)EventsWin rateAvg returnSPYExcess
Heavy accumulation — 3+ tracked funds increased together1181.8%+12.1%+2.1%+9.9%
Share count tripled (3x)1100.0%+14.0%+3.7%+10.3%

Measured from SEC 13F filings: entry at the close on the first trading day after each quarter’s filing deadline, exit one quarter later on the same rule, dividend-adjusted closes. Past records do not guarantee future results — see Track Record and Methodology.

Also held by the tracked funds that hold ABBV — ranked by lift, the co-holding pattern described in Methodology: ISHARES RUSSELL 1000 ETF (IWB) · AMGEN INC (AMGN) · 3M CO (MMM) · CINTAS CORP (CTAS) · NORTHROP GRUMMAN CORP /DE/ (NOC) · ISHARES MSCI ACWI EX US ETF (ACWX) · Corteva, Inc. (CTVA) · GENERAL MILLS INC (GIS).

Filings audit: every filing lens on AbbVie Inc. (ABBV), scored — GetCoattail Research.

Recent 8-K filings

FiledItemsSource
Nov 2, 20265.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain OfficersSEC filing
Oct 30, 20262.02 Results of Operations and Financial Condition · 9.01 Financial Statements and ExhibitsSEC filing
Oct 15, 20265.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain OfficersSEC filing

Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.

Related

ISHARES RUSSELL 1000 ETF (IWB) · Filings audit: every filing lens on AbbVie Inc. (ABBV), scored · Practice timing on ABBV

One email a week: the week’s new filings and research. Subscribe free

← AAPL  ·  ABCB →

Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.